Results 171 to 180 of about 362,063 (315)

Sexual and Reproductive Healthcare Among Youth With Autism and ADHD: A Population‐Based Study From Sweden

open access: yesAutism Research, EarlyView.
ABSTRACT Youth with autism spectrum disorder or attention‐deficit/hyperactivity disorder (ADHD) may face barriers to sexual and reproductive health (SRH) services. Yet, data on preventive SRH service use remain limited, especially digital care. This population‐based registry study investigated whether patterns of SRH service use differed by digital ...
Lovisa Hellsten   +6 more
wiley   +1 more source

KATENA: a verifiable governance architecture for encrypted cloud storage systems. [PDF]

open access: yesFront Big Data
Rodríguez-Aragón JF   +3 more
europepmc   +1 more source

‘They Even Have the Capacity, but the Places Aren't Prepared to Receive Them’: Community Environment and Participation of Autistic Children in a Family‐Engaged Research Analysis

open access: yesAutism Research, EarlyView.
ABSTRACT To examine the associations between community environmental barriers and support and the participation of autistic children, and to interpret these findings from the perspective of caregivers engaged as research partners. This cross‐sectional observational study employed a mixed‐methods design.
Léia Cordeiro de Oliveira   +7 more
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy